RY 170.06 -0.4391% SHOP 146.45 -0.0137% TD 78.54 0.4605% ENB 63.205 1.1766% BN 79.82 0.9741% TRI 221.22 -0.8738% CNQ 45.03 -0.9241% CP 106.44 0.2354% CNR 143.84 -0.3326% BMO 140.27 0.5808% BNS 73.51 0.9753% CSU 4258.9448 -0.9172% CM 88.77 -0.3144% MFC 42.81 0.6584% ATD 74.89 -0.4784% NGT 57.67 2.2155% TRP 66.61 0.6954% SU 56.91 0.3173% WCN 252.55 -0.7038% L 176.59 -2.6301%
Last update at 2025-01-14T18:30:00Z
HLS Therapeutics Announces CFO Departure
Mon 18 Dec 23, 11:30 AMSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates
Wed 15 Nov 23, 10:02 AMHLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call
Thu 26 Oct 23, 10:30 AMAnalysts Expect Breakeven For HLS Therapeutics Inc. (TSE:HLS) Before Long
Fri 18 Aug 23, 10:30 AMHLS Therapeutics Announces Updates to its Credit Agreement
Mon 14 Aug 23, 10:30 AMHLS Therapeutics Announces Q2 Fiscal 2023 Financial Results
Thu 10 Aug 23, 10:30 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -23.72200M | -11.80800M | -16.29900M | -20.46300M | -28.80300M |
| Minority interest | - | - | - | - | - |
| Net income | -23.59800M | -13.11700M | -15.33100M | -19.55200M | -24.80600M |
| Selling general administrative | 17.73M | 17.40M | 18.48M | 18.09M | 14.46M |
| Selling and marketing expenses | 17.85M | 14.66M | 12.90M | 6.26M | 4.32M |
| Gross profit | 56.49M | 56.04M | 52.48M | 52.23M | 58.82M |
| Reconciled depreciation | 34.40M | 30.26M | 33.19M | 32.51M | 32.40M |
| Ebit | -13.44000M | -6.24000M | -11.25600M | -4.04300M | -10.95600M |
| Ebitda | 20.96M | 24.02M | 21.93M | 28.47M | 21.44M |
| Depreciation and amortization | 34.40M | 30.26M | 33.19M | 32.51M | 32.40M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -13.44000M | -6.24000M | -11.25600M | -4.04300M | -10.95600M |
| Other operating expenses | 74.96M | 66.29M | 68.20M | 58.79M | 53.78M |
| Interest expense | 7.32M | 6.96M | 6.31M | 7.70M | 17.11M |
| Tax provision | -0.12400M | 1.31M | -0.96800M | -0.91100M | -3.99700M |
| Interest income | 0.06M | 0.04M | 0.32M | 0.58M | 0.36M |
| Net interest income | -7.26000M | -6.91200M | -5.98500M | -7.11400M | -35.70500M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.12400M | 1.31M | -0.96800M | -0.91100M | -3.99700M |
| Total revenue | 61.47M | 60.01M | 56.11M | 54.16M | 61.41M |
| Total operating expenses | 69.98M | 62.32M | 64.57M | 56.86M | 51.18M |
| Cost of revenue | 4.98M | 3.97M | 3.62M | 1.93M | 2.60M |
| Total other income expense net | -10.28200M | -5.56800M | -5.04300M | -16.42000M | -17.84700M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -23.59800M | -13.11700M | -15.33100M | -19.55200M | -24.80600M |
| Net income applicable to common shares | -23.59800M | -13.11700M | -15.33100M | -19.55200M | -24.80600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 209.06M | 241.65M | 275.90M | 303.91M | 319.67M |
| Intangible assets | 162.34M | 195.02M | 229.18M | 253.40M | 252.05M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.92M | 3.56M | 4.52M | 2.17M | 2.11M |
| Total liab | 111.36M | 116.33M | 115.17M | 134.66M | 141.47M |
| Total stockholder equity | 97.70M | 125.32M | 160.74M | 169.25M | 178.20M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.72M | 6.01M | 5.75M | 11.28M | 27.63M |
| Common stock | 262.13M | 265.21M | 265.92M | 257.41M | 248.69M |
| Capital stock | 262.13M | 265.21M | 265.92M | 257.41M | 248.69M |
| Retained earnings | -175.45700M | -148.44900M | -119.85700M | -101.57500M | -81.46800M |
| Other liab | - | 1.38M | 2.54M | - | 5.08M |
| Good will | - | - | - | - | - |
| Other assets | - | 1.13M | 1.40M | 3.21M | 3.25M |
| Cash | 21.95M | 20.72M | 21.18M | 20.61M | 47.08M |
| Cash and equivalents | - | 20.72M | 21.18M | 20.61M | 47.08M |
| Total current liabilities | 26.69M | 31.19M | 27.67M | 35.64M | 47.14M |
| Current deferred revenue | 5.71M | - | - | 5.06M | 5.82M |
| Net debt | 65.67M | 76.62M | 76.39M | 86.51M | 46.03M |
| Short term debt | 5.16M | 13.58M | 12.61M | 10.14M | 6.04M |
| Short long term debt | 4.69M | 13.06M | 12.00M | 9.75M | 5.62M |
| Short long term debt total | 87.62M | 97.34M | 97.57M | 107.12M | 93.11M |
| Other stockholder equity | 13.87M | 13.82M | 11.72M | 11.39M | 11.52M |
| Property plant equipment | - | 1.13M | 1.57M | 1.38M | 1.28M |
| Total current assets | 44.09M | 44.37M | 43.75M | 45.91M | 63.10M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -69.70000M | -68.44500M | -84.15500M | -73.85100M |
| Short term investments | - | - | - | - | - |
| Net receivables | 10.69M | 11.19M | 11.51M | 12.50M | 11.86M |
| Long term debt | 82.05M | 83.28M | 84.13M | 96.20M | 86.58M |
| Inventory | 9.53M | 8.90M | 8.93M | 10.63M | 2.06M |
| Accounts payable | 14.11M | 11.59M | 9.32M | 14.22M | 13.47M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2.83800M | -5.26000M | 2.96M | 2.02M | -0.53700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 257.41M | 248.69M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.62M | 0.67M | 0.71M | 2.03M | 2.19M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 164.97M | 197.28M | 232.15M | 258.00M | 256.57M |
| Capital lease obligations | 0.88M | 1.01M | 1.43M | 1.17M | 0.90M |
| Long term debt total | - | 83.76M | 84.96M | 96.98M | 87.07M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -10.14800M | -4.51000M | -44.67700M | -15.35900M | -14.58100M |
| Change to liabilities | 3.24M | -3.64600M | -0.07000M | -2.03100M | -0.73700M |
| Total cashflows from investing activities | -10.14800M | -4.51000M | -44.67700M | -15.35900M | -14.58100M |
| Net borrowings | -0.44100M | -11.13700M | 13.34M | -5.45300M | -52.52100M |
| Total cash from financing activities | -6.85600M | -11.39800M | 9.56M | 23.95M | -42.85600M |
| Change to operating activities | -0.70700M | -1.73900M | -1.23600M | -1.95700M | 0.22M |
| Net income | -23.59800M | -13.11700M | -15.33100M | -19.55200M | -24.80600M |
| Change in cash | -0.45600M | 0.57M | -26.46600M | 36.15M | -25.28900M |
| Begin period cash flow | 21.18M | 20.61M | 47.08M | 10.93M | 36.22M |
| End period cash flow | 20.72M | 21.18M | 20.61M | 47.08M | 10.93M |
| Total cash from operating activities | 16.94M | 16.43M | 9.34M | 26.41M | 32.75M |
| Issuance of capital stock | - | - | 0.00000M | 37.33M | 19.47M |
| Depreciation | 34.40M | 30.26M | 33.19M | 32.51M | 32.40M |
| Other cashflows from investing activities | -10.00000M | -3.82000M | -12.05000M | -12.80000M | -13.80000M |
| Dividends paid | 4.96M | 5.12M | 4.75M | 4.33M | 1.05M |
| Change to inventory | -0.62200M | 1.77M | -8.07700M | -0.50100M | -0.23600M |
| Change to account receivables | -0.07100M | 1.04M | 1.52M | 6.06M | 7.29M |
| Sale purchase of stock | -0.99800M | -0.04700M | 1.64M | 0.05M | -0.92400M |
| Other cashflows from financing activities | 9.54M | 4.91M | 20.98M | -3.59700M | 92.17M |
| Change to netincome | 4.59M | 2.30M | -0.84600M | 11.90M | 6.97M |
| Capital expenditures | 10.15M | 4.51M | 44.68M | 2.56M | 0.78M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.55M | -3.02100M | -7.66500M | 1.55M | 6.46M |
| Stock based compensation | 2.92M | 2.35M | 2.53M | 3.76M | 0.64M |
| Other non cash items | 1.53M | -1.18700M | -0.89400M | 10.38M | 23.51M |
| Free cash flow | 6.79M | 11.92M | -35.33300M | 23.85M | 31.97M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HLS HLS Therapeutics Inc |
0.03 0.79% | 3.82 | - | 185.19 | 1.97 | 1.05 | 2.37 | 8.04 |
| BHC Bausch Health Companies Inc |
- -% | 10.65 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
-0.08 3.90% | 1.97 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| TLRY Tilray Inc |
-0.01 0.58% | 1.70 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| CRON Cronos Group Inc |
0.03 1.08% | 2.81 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2
| Name | Title | Year Born |
|---|---|---|
| Mr. Gregory David Gubitz B.A., L.L.B., LL.B | Co-Founder & Chairman | 1957 |
| Mr. Gilbert Godin | Co-Founder, CEO & Director | 1959 |
| Mr. Tim Hendrickson M.B.A. | Chief Financial Officer | 1972 |
| Mr. Sanjiv Sharma | Chief Commercial Officer | 1956 |
| Mr. Ryan C. Lennox B.A., J.D. | Sr. VP of Legal, HR & Compliance and Corp. Sec. | 1981 |
| David Spence | Corp. Controller | 1968 |
| Mr. Craig Stuart Millian M.B.A. | CEO & Director | 1968 |
| Mr. John Hanna CPA, CGA, M.B.A. | CFO & Non-Independent Director | 1965 |
| Dr. Jason A. Gross Pharm.D. | Vice President of Scientific Affairs | 1965 |
| Mr. Ryan C. Lennox B.A., J.D. | Senior VP of Legal, HR & Compliance and Corporate Secretary | 1981 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...